Robert J. Weinstock, MD
Private Practice
The Eye Institute of West Florida
Largo, FL
William F. Wiley, MD
Medical Director
Cleveland Eye Clinic
Division of Midwest Vision Partners
Cleveland, OH
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Robert J. Weinstock, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, Bausch + Lomb, Beyeonics, EyePoint Pharmaceuticals, Johnson & Johnson Vision, Lensar, and Visus. Speaker's Bureau: Johnson & Johnson Vision. Shareholder: Eyesafe, RPS, RxSight, TissueTech, uBeam, and Visus.
William F. Wiley, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, Allergan, Bausch + Lomb, Carl Zeiss Meditec, Dompé, Imprimis, and RxSight.
Akaanksh Shetty, MD has no financial relationships with ineligible companies
Allison Shuren, MSN, JD has no financial relationships with ineligible companies
Arjan Hura, MD has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AcuFocus, Alcon, Allergan/AbbVie, BVI, Rayner, Twenty Twenty Therapeutics, Tarsus, Visus, and Carl Zeiss Meditec. Grant / Research Support: Alcon. Speakers Bureau: Alcon
Blake Williamson, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Allergan, Carl Zeiss Meditec, Johnson & Johnson Vision, New World Medical, Quidel Corporation, and Sight Sciences. Speaker: Glaukos.
Caroline Watson, MD has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, Microsurgical Technologies, AbbVie, Visus, Tarsus, Bausch + Lomb, Johnson & Johnson, Lumenis, Dompe, Carl Zeiss Meditec, BVI/Beyeonics, Corza Medical, and Rx Sight
Carrie Jacobs has no financial relationships with ineligible companies
Cathleen McCabe, MD has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Abbvie Alcon Allergan Bausch+Lomb Dompe EyePoint Glaukos Ivantis Novartis Ocular Innovations Ocular Therapeutix Omeros Science Based Health Sight Sciences Sun Ophthalmics Tarsus, and Carl Zeiss Meditec. Advisory Board:
Craig Piso, PhD has no financial relationships with ineligible companies
Cristos Infantides, MD has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant and Advisory Board: AbbVie, Ace Vision Group, Acufocus, Alcon, BVI, Centricity Vision, Johnson & Johnson, New World Medical, Spect, Tarsus Pharmaceuticals, Carl Zeiss Meditec, Hu-Med Technologies. Grant/Research Support: Johnson & Johnson and New World Medical. Shareholder: Oyster Point.
Cynthia Matossian, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Aerie Pharmaceuticals, Alcon, Allergan, Aramis Biosciences, Bausch + Lomb, Bruder Healthcare, Carl Zeiss Meditec, Checked-Up, Conclusn, Dompé, EyePoint Pharmaceuticals, Eyevance, Glint Pharmaceuticals, Guardion Health Services, Imprimis Pharmaceuticals, Johnson & Johnson Vision, Kala Pharmaceuticals, LacriSciences Vision, legrande Health, Lenstec, lumenis, Marco, MDBackline, MiCare, MYZE, Novartis, NuLids, Ocular Science, Olympic, Omeros, Osmotica Pharmaceuticals, Physician Recommended Nutriceuticals, Quidel, Reger-Eyes, StepWise Medical, Sun Pharmaceutical Industries, TearLab, TearScience, TissueTech, Visionology, and Visus Therapeutics. Grant/Research Support: Dompé, Imprimis Pharmaceuticals, Johnson & Johnson, and Novartis. Speaker's Bureau: Alcon, Allergan, Carl Zeiss Meditec, EyePoint Pharmaceuticals, Eyevance, Guardion Health Services, Imprimis Pharmaceuticals, Johnson & Johnson Vision, Kala Pharmaceuticals, LacriSciences Vision, Lumenis, Novartis, NuLids, Olympic, Omeros, Physician Recommended Nutriceuticals, Sun Pharmaceutical Industries, TearLab, TearScience, and TissueTech. Shareholder: Checked-Up, Physician Recommended Nutriceuticals, and Strathspey Crown.
Dagny Zhu, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Alchemy Vision, Alcon, Allergan/Abbvie, Bausch + Lomb, Bruder, Entelexo, Eyesafe, Eyenovia, IrisVisison, Johnson & Johnson, Lensar, Ocuphire, Sight Sciences, Tarsus, and Visus. Grant/Research Support: Alcon and Lensar. Speakers Bureau: Allergan/AbbVie and Santen. Shareholder: Glaukos
Debbie Davis has no financial relationships with ineligible companies
Denise Visco, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Carl Zeiss Meditec, Lensar, Rayner, Cassini, and PRN. Grant/Research Support: Oyster Point and Lensar. Speakers Bureau: Sun Ophthalmics.
Eric Weinberg has a financial agreement or affiliation with the following ineligible companies in the form of Shareholder: RxSight
Frank Bucci, MD has a financial agreement or affiliation with the following ineligible companies in the form of Grant/Research Support: Johnson & Johnson Vision.
Gary Wortz, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Alcon, Bausch + Lomb, Carl Zeiss Meditec, Dompé, Johnson & Johnson Vision, Lensar, Ocular Science & Ocuphire, and Tarsus. Speakers Bureau: Avellino. Stockholder: Arcuate Innovations, Johnson & Johnson, Ocular Science & Omega Ophthalmics
Inder Paul Singh, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Aerie, Allergan, Bausch + Lomb, Carl Zeiss Meditec, Elios, Glaukos, Ivantis, MMD, New World Medical, Ocular Therapeutix, Santen, and Sight Sciences. Speaker: Aerie, Allergan, Bausch + Lomb, Ivantis, Ocular Therapeutix, and Sight Sciences. Shareholder: CoFI.
Ivan Mac, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Alcon, Johnson & Johnson, Tarsus, Staar Surgical, and Santen. Speakers Bureau: Johnson & Johnson, Alcon, Sun Pharmaceuticals. Shareholder: RxSight and Visionary Venture Group
Jack Chapman MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Alcon, Santen, RVL Pharmaceutical, and Sun Pharmaceutical. Grant/Research Support: Alcon. Advisory Board: RVL Pharmaceuticals, Sun Pharmaceutical, and Visiox Pharma. Speakers Bureau: Alcon and RVL. Shareholder: Visiox Pharma
James Lehmann, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Johnson & Johnson, Lensar, and Diamatrix. Grant/Research Support: Glaukos, Johnson & Johnson, RxSight, and Lensar. Speakers Bureau: RxSight. Shareholder: RxSight
James Murphy, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant, Grant/Research Support, and Speakers Bureau: NOVA Eye and Sight Sciences.
Jared Younger, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Johnson & Johnson and Ceyeber Third Eye Corporation. Shareholder: Evolus, Aeon Biopharma, Crown Sterling, Strathspey Crown Holdings.
Jeffrey Whitman, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Alcon, Allergan, Johnson & Johnson, Bausch + Lomb, and Glaukos. Speakers Bureau: Alcon.
James Katz, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant and Advisor: Alcon, Allergan, Avellino Labs, Bausch + Lomb, Carl Zeiss Meditec, Cassini Technologies B.V., Centricity Vision, Eyevance Pharmaceuticals, Johnson & Johnson Vision, Kala Pharmaceuticals, LEGRANDE Health, Lenticular Research Group, Novartis, Ocular Science, Ocuphire Pharma, Refocus Group, Tarsus Pharmaceuticals, and Visus Therapeutics. Grant/Research Support: Allergan, Cassini Technologies B.V., and Refocus Group. Speaker: Alcon and Novartis. Shareholder: Centricity Vision, Inc, LEGRANDE Health, Lenticular Research Group, Ocular Science, Orasis Pharmaceuticals, and Tarsus Pharmaceuticals.
Jim Loden, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant and Speakers Bureau: Johnson & Johnson
Joaquin De Rojas, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Sun Pharmaceuticals, TearLab, Oculus Biologics, Johnson & Johnson. Grant/Research Support: Johnson & Johnson and TearLab. Speakers Bureau: Sun Pharmaceuticals.
Kenneth Maverick, MD has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant and Speakers Bureau: RXSight, Glaukos, Johnson and Johnson
Kris Pugh, MD has no financial relationships with ineligible companies
Mark Kantos, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Alcon, Allergan, Johnson & Johnson, Taursis, Glaukos, PRN, Horizon, and Carl Zeiss Meditec
Mary Pat Johnson has no financial relationships with ineligible companies
Mitch Jackson, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant and Speakers Bureau: Alcon, Bausch & Lomb, Johnson & Johnson, RxSight, Eyepoint Pharmaceuticals, Sun Pharmaceuticals, ACE Vision Group, Allergan, Carl Zeiss Meditec, Trukera, Ocular Therapeutix, Omeros/Rayner, Ocuphire, Tarsus, Centricity, and LENSAR. Grant/Research Support: Alcon and Johnson & Johnson. Shareholder: ACE Vision Group, Calhoun Vision, Ocuphire, and Myze
Mohamed Mohamed, MD has no financial relationships with ineligible companies
J. Morgan Micheletti, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Alcon, Allergan, Bausch + Lomb, Beaver-Visitec International, Carl Zeiss Meditec, Centricity Vision, Glaukos, Johnson & Johnson, New World Medical, RxSight, Tarsus, Visus. Speakers Bureau: Alcon, Diamatrix, Johnson & Johnson, and RxSight. Grant/Research Support: Alcon, Allergan, and Johnson & Johnson. Patents/Royalties: Diamatrix and Ophthalmic New-Innovations of Texas.
P. Dee Stephenson, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Atia, Cassini, Guardian Health, Lensar, Ocular Therapeutix, Carl Zeiss Meditec. Speakers Bureau: Atia, Alcon, Bausch + Lomb, Bruder, Cassini, Lensar, Ocular Therapeutix, Sun Ophthalmics, Carl Zeiss Meditec. Grant/Research Support: Oyster Point and Bausch + Lomb
Parag Majmudar, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Carl Zeiss Meditec
Pat Morris has no financial relationships with ineligible companies
Paul Walton, MD has no financial relationships with ineligible companies
Priya Matthews, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Sun Pharma, Dompe, Precise Bioscience, Johnson & Johnson, Alcon, and WL Gore. Speakers Bureau: Sun Pharma, Dompe, Precise Bioscience, Johnson & Johnson, and Alcon.
Scott LaBorwit, MD has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon and Sight Science. Shareholder: Vision Innovation Partners
Shamik Bafna, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Alcon, Bearer Visitec, Carl Zeiss Meditec, Sight Sciences, and Ivantis. Speaker’s Bureau: Rx Sight.
Sheri Rowen, MD has a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Alcon, Allergan, Bausch + Lomb, Oyster Point, Kala, Johnson & Johnson, Novartis, Azura, Ocuterra, Orasis, and Carl Zeiss Meditec. Grant/Research Support: Alcon and Novartis. Speakers Bureau: Alcon, Bausch + Lomb, and Kala. Shareholder: Ocuterra and Orasis.
Stephen Slade, MD has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, Carl Zeiss Meditec, Stroma, Staar, and RxSight. Shareholder: Aurion, Stroma, RxSight, and Neurolens
Steven Dell, MD has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Johnson and Johnson, Alcon, Bausch and Lomb, Allergan, LENZ Therapeutics, Optical Express, Tracey Technologies, and Lumenis. Shareholder: Johnson & Johnson, Lenz Therapeutics, Tracey Technologies
Tom Frinzi has a financial agreement or affiliation with the following ineligible companies in the form of Shareholder and Advisory Board: Staar Surgical, iOR Partners, CorneaGen, ViaLase, and Aurion Biotech.
Tom Harvey, MD has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Anodyne and PRN. Grant/Research Support: Lenstec and Carl Zeiss Meditec. Shareholder: RPS
William Link, PhD has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AEYE Health, Inc.; Aquea Health, Inc. Shareholder: Acufocus, Inc., Allegro Ophthalmics, Aurion Biotech, CorneaGen, Equinox Ophthalmic, Lensar, Neurolens, Ocutrx, Praxis Vision, RxSight, Surface, Tarsus, TearClear, ViaLase
The Evolve staff, the American College of Eye Surgeons (ACES), the American Board of Eye Surgery (ABES) and the Society for Excellence in Eyecare (SEE), planners and peer reviewer have no financial relationships with ineligible companies.
